LONDON--Drugs that combat obesity could for the first time be included on the World Health Organization’s “essential medicines list,” used to guide government purchasing decisions in low ...
Dr. Carroll is the chief health officer of Indiana University and writes often on health policy. We like to think we understand the drugs we take, especially after rigorous trials have proved ...
As prescriptions for Ozempic soar, the drug and others like it are still reaching only a fraction of the population who could ...
People desperate to lose weight are getting prescriptions for the diabetes drug, without having diabetes. Use jumped ...
Almost 1,900 doctors signed up to take this year's exam to become certified in treating obesity, according to the American ...
We’ll send you a myFT Daily Digest email rounding up the latest The FT View news every morning. It is somewhat ironic that Denmark’s economic growth in the first half of the year was driven ...
We like to think we understand the drugs we take, especially after rigorous trials have proved their efficacy and safety. But sometimes, we know only that medications work; we just don’t know why.
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the ...
Ozempic commercials are, at this point, ubiquitous and while that’s an anecdotal example, it also represents confirmation that obesity drugs are the next big thing in the pharmaceuticals industry.
A host of technical, institutional and economic issues pose grave challenges to the development and deployment of safe and effective anti-obesity medications. The morbidity and mortality risks ...
Share on Pinterest Ozemic and similar GLP-1 drugs can cost as much as four times more in the U.S. than they do in other countries. Mario Tama/Getty Images The list prices for Ozempic, Wegovy, and ...
Annual sales of anti-obesity drugs, which today total about $2.2 billion, could reach more than $40 billion globally by 2030, according to Bloomberg analysts. More stories like this are available ...
